Blog | BioInformant

Greenstone Biosciences Wins Breakthrough T1D Grant to Model Diabetes Using Patient-Derived iPSCs

August 22, 2026 By BioInformant Team Leave a Comment

Greenstone Biosciences Awarded Breakthrough T1D Grant to Advance Islet Cell Platform

PALO ALTO, Calif. –Greenstone Biosciences has been awarded a Breakthrough T1D Industry Discovery and Development Partnership (IDDP) grant to develop a T1D-derived islet cell platform aimed at understanding and protecting insulin-producing β cells in people with type 1 diabetes. With support from Breakthrough T1D, Greenstone plans to create induced pluripotent stem cells (iPSCs) from a diverse group of T1D patients and develop 3D pancreatic islet organoids, lab-grown structures containing insulin-producing β cells, to examine how these cells respond to inflammation, metabolic stress, and potential protective therapies. [Read more…]

IPS HEART’s iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone

August 17, 2026 By BioInformant Team Leave a Comment

IPS HEART Secures 8th FDA Regulatory Milestone with Rare Pediatric Drug Designation for Cardiomyopathy Associated with Muscular Dystrophies

HOUSTON–IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. [Read more…]

Cell Therapy CDMO Cellipont Bioservices Celebrates Major Manufacturing Milestone: Releases 100th GMP Batch

August 16, 2026 By BioInformant Team Leave a Comment

Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facility

THE WOODLANDS, Texas, July 28, 2026 — Cellipont Bioservices, a cell therapy contract development and manufacturing organization, announced the successful release of its 100th GMP batch at its manufacturing facility in The Woodlands, Texas.

The achievement is especially significant given that Cellipont initiated GMP manufacturing operations at the facility in June 2025. Reaching 100 GMP batch releases in approximately one year reflects the strength of the company’s operational infrastructure, the growing demand from its clients, and the dedication of its cross-functional teams. [Read more…]

Aspen Neuroscience Receives FDA RMAT for Sasineprocel (ANPD001), an Autologous iPSC-Based Therapy for PD

August 16, 2026 By BioInformant Team Leave a Comment

SAN DIEGO, July 30, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson’s Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). [Read more…]

Data-Driven Healthcare Starts With Better Patient Insights

August 13, 2026 By Marie Carroll Leave a Comment

Modern medicine generates massive amounts of digital information every single day. Hospitals routinely track everything from heart rates and lab results to medication schedules with extreme precision. These measurements build a comprehensive record of clinical care inside the facility. [Read more…]